Article Text

Download PDFPDF

4CPS-028 Effectiveness and safety of cenobamate: experience in a third-level hospital
  1. B Ardizone,
  2. FJ Bécares Martínez,
  3. M Hernández Segurado,
  4. E Tortajada Esteban,
  5. L García Jiménez,
  6. N Barreras Ruiz,
  7. L Jiménez Navarro
  1. Hospital Universitario Fundacion Jiménez Díaz, Pharmacy, Madrid, Spain


Background and importance More than one-third of patients with epilepsy have uncontrolled seizures despite being treated with two or more anti-seizure medications (ASM); this condition is known as refractory or drug-resistant epilepsy. Cenobamate is a new ASM that has been recently approved by the European Medicines Agency for the adjunctive treatment of focal-onset seizures in adults with drug-resistant epilepsy. In the Spanish system, cenobamate is a drug that is dispensed in hospitals and, since August 2020, access to it has been made through the compassionate use programme. Because of its newness, real-world data regarding cenobamate use are currently very limited.

Aim and objectives The aim of this study was to evaluate the effectiveness and safety of cenobamate in real-world practice.

Material and methods We conducted a single-centre, retrospective study of patients who received cenobamate in our hospital between September 2020 and September 2021.The patients included in the study must have received cenobamate for at least 3 months. Demographic and clinical variables were collected by reviewing medical records. The efficacy outcome was the proportion of patients who exhibited a 50% or greater reduction in the monthly seizure frequency from baseline (50% responder rate). We also recorded adverse events (AEs) and estimated the rate of discontinuation of treatment.

Results All the patients included in the study (n=30) were adults with focal-onset epilepsy who had uncontrolled seizures despite a history of treatment with ASMs. Patients were treated with one to five concomitant ASMs during the study period and 43.3% of them reduced the number of ASMs with one or two. The daily dose of cenobamate ranged from 50 to 400 mg/day. The 50% responder rate was 53.3%, with a median of 50% (IQR 31.2; 73.3) in the reduction of monthly seizure frequency.73.3% of patients had nervous system disorders (somnolence, dizziness, dysarthria, etc.), 16.67% had gastrointestinal AEs and 6.67% showed skin disorders (one of them had rash erythematous). The discontinuation rate because of AEs was 13.3%.

Conclusion and relevance The effectiveness and safety data obtained are similar to those of the clinical trial. We found that adjunctive treatment with cenobamate allows a reduction in the number of concomitant ASMs in an important proportion of the patients.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.